{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:11Z","timestamp":1794047411234,"version":"4.8.0"},"reference-count":30,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and toxicities of alloHCT after receipt of CAR T are limited. We report a multicenter retrospective study assessing the safety, toxicities, and outcomes of alloHCT in LBCL patients following CAR T failure. Eighty-eight patients with relapsed, refractory LBCL received an alloHCT following anti-CD19 CAR T failure. The median number of lines of therapy between CAR T infusion and alloHCT was one (range, 0-7). Low intensity conditioning was used in 77% (n=68) and peripheral blood was the most common graft source (86%, n=76). The most common donor types were matched unrelated donor (39%), followed by haploidentical (30%) and matched related donor (26%). Median follow-up of survivors was 15 months (range, 1-72). One-year overall survival, progression-free survival, and graft-versus-host disease-free relapse-free survival were 59%, 45%, and 39% respectively. One-year non-relapse mortality and progression\/relapse were 22% and 33% respectively. On multivariate analysis, &lt;2 lines of intervening therapy between CAR T and alloHCT and complete response at time of alloHCT were associated with better outcomes. In conclusion, alloHCT after CAR T failure can provide durable remissions in a subset of patients.<\/jats:p>","DOI":"10.3324\/haematol.2022.281242","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T15:10:13Z","timestamp":1657811413000},"page":"98-109","source":"Crossref","is-referenced-by-count":81,"title":["Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma"],"prefix":"10.3324","volume":"108","author":[{"given":"Joanna","family":"Zurko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ramdial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Alarcon","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav. N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh H.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Samara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Della","family":"Pia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Reagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"42899","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1):45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"42900","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"42901","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"42902","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20(1):31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"42903","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Tam CS, Borchmann P. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22(10):1403-1415.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"42904","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Hunter BD, Redd R. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020; 38(27):3095-3106.","DOI":"10.1200\/JCO.19.02103"},{"key":"42905","doi-asserted-by":"crossref","unstructured":"Nastoupil LJ, Jain MD, Feng L. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38(27):3119-3128.","DOI":"10.1200\/JCO.19.02104"},{"key":"42906","doi-asserted-by":"crossref","unstructured":"Vercellino L, Di Blasi R, Kanoun S. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020; 4(22):5607-5615.","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"42907","unstructured":"Spiegel JY, Dahiya S, Jain MD. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021; 137(13):1832-1835."},{"key":"42908","doi-asserted-by":"crossref","unstructured":"Dreger P, Sureda A, Ahn KW. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019; 3(3):360-369.","DOI":"10.1182\/bloodadvances.2018027748"},{"key":"42909","doi-asserted-by":"crossref","unstructured":"Shadman M, Gauthier J, Hay KA. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019; 3(20):3062-3069.","DOI":"10.1182\/bloodadvances.2019000593"},{"key":"42910","unstructured":"Spiegel JY, Dahiya S, Jain MD. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel. Blood. 2021; 137(13):1832-1835."},{"key":"42911","doi-asserted-by":"crossref","unstructured":"Zurko JC, Epperla N, Nizamuddin I. Outcomes and treatment patterns in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy. Blood. 2021; 138(Suppl 1):S884.","DOI":"10.1182\/blood-2021-147433"},{"key":"42912","doi-asserted-by":"crossref","unstructured":"Caimi PF, Ai WZ, Alderuccio JP. Efficacy and safety of loncastuximab tesirine (ADCT-402) in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2020; 136(Suppl 1):S35-37.","DOI":"10.1182\/blood-2020-137524"},{"key":"42913","doi-asserted-by":"crossref","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7):978-988.","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"42914","doi-asserted-by":"crossref","unstructured":"Sehn LH, Herrera AF, Flowers CR. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38(2):155-165.","DOI":"10.1200\/JCO.19.00172"},{"key":"42915","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity asociated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"42916","doi-asserted-by":"crossref","unstructured":"Lee DW, Gardner R, Porter DL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"42917","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Tummala S, Kebriaei P. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15(1):47-62.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"42918","doi-asserted-by":"crossref","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018; 11(1):35.","DOI":"10.1186\/s13045-018-0571-y"},{"key":"42919","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"42920","doi-asserted-by":"crossref","unstructured":"Harris AC, Young R, Devine S. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GvHD International Consortium. Biol Blood Marrow Transplant. 2016; 22(1):4-10.","DOI":"10.1016\/j.bbmt.2015.09.001"},{"key":"42921","doi-asserted-by":"crossref","unstructured":"Jagasia MH, Greinix HT, Arora M. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015; 21(3):389-401.","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"42922","doi-asserted-by":"crossref","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021; 27(8):642-649.","DOI":"10.1016\/j.jtct.2021.04.007"},{"key":"42923","doi-asserted-by":"crossref","unstructured":"Hamadani M, Gopal AK, Pasquini M. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022; 6(2):486-494.","DOI":"10.1182\/bloodadvances.2021005788"},{"key":"42924","doi-asserted-by":"crossref","unstructured":"Epperla N, Ahn KW, Khanal M. Impact of reduced-intensity conditioning regimens on outcomes in diffuse large B cell lymphoma undergoing allogeneic transplantation. Transplant Cell Ther. 2021; 27(1):58-66.","DOI":"10.1016\/j.bbmt.2020.09.014"},{"key":"42925","doi-asserted-by":"crossref","unstructured":"Bacher U, Klyuchnikov E, Le-Rademacher J. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. Blood. 2012; 120(20):4256-4262.","DOI":"10.1182\/blood-2012-06-436725"},{"key":"42926","doi-asserted-by":"crossref","unstructured":"Fenske TS, Ahn KW, Graff TM. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016; 174(2):235-248.","DOI":"10.1111\/bjh.14046"},{"key":"42927","doi-asserted-by":"crossref","unstructured":"Serna DS, Lee SJ, Zhang MJ. Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada. J Clin Oncol. 2003; 21(20):3754-3760.","DOI":"10.1200\/JCO.2003.03.133"},{"key":"42928","doi-asserted-by":"crossref","unstructured":"Baker KS, Loberiza FR, Yu H. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol. 2005; 23(28):7032-7042.","DOI":"10.1200\/JCO.2005.01.7269"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281242\/74639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281242\/75154","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10714\/74639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:00Z","timestamp":1794045720000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281242","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}